PE20211449A1 - INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSES - Google Patents

INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSES

Info

Publication number
PE20211449A1
PE20211449A1 PE2020001395A PE2020001395A PE20211449A1 PE 20211449 A1 PE20211449 A1 PE 20211449A1 PE 2020001395 A PE2020001395 A PE 2020001395A PE 2020001395 A PE2020001395 A PE 2020001395A PE 20211449 A1 PE20211449 A1 PE 20211449A1
Authority
PE
Peru
Prior art keywords
cell
antigen
adjuvant
entry
modified
Prior art date
Application number
PE2020001395A
Other languages
Spanish (es)
Inventor
Scott Loughhead
Leeann Talarico
Alfonso Vicente-Suarez
Matt Booty
Howard Bernstein
Katarina Blagovic
Armon R Sharei
Kelan Hlavaty
Original Assignee
Sqz Biotechnologies Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sqz Biotechnologies Co filed Critical Sqz Biotechnologies Co
Priority claimed from PCT/US2019/021705 external-priority patent/WO2019178006A2/en
Publication of PE20211449A1 publication Critical patent/PE20211449A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Referido a una celula T modificada que comprende un antigeno y un adyuvante, en donde el antigeno es exogeno a la celula T modificada y comprende un epitopo inmunogenico, y en donde el adyuvante esta presente en forma intracelular. Ademas, el antigeno que comprende la secuencia de aminoacidos de cualquiera de las SEQ ID NOs: 18-25. Un proceso que comprende: a) pasar una suspension celular que comprende una celula T de entrada a traves de una constriccion de deformacion celular, en donde un diametro de la constriccion es una funcion de un diametro de la celula T de entrada en la suspension, causando asi perturbaciones de la celula T de entrada suficientemente grandes para que el antigeno y el adyuvante pasen a traves para formar una celula T de entrada perturbada; y b) incubar la celula T de entrada perturbada con el antigeno y el adyuvante durante un tiempo suficiente para permitir que el antigeno y el adyuvante ingresen en la celula T de entrada perturbada; generando asi la celula T modificada. Tambien se refiere a metodos de uso de dichas celulas T para modular una respuesta inmune.Refers to a modified T cell comprising an antigen and an adjuvant, wherein the antigen is exogenous to the modified T cell and comprises an immunogenic epitope, and wherein the adjuvant is present in intracellular form. In addition, the antigen comprising the amino acid sequence of any of SEQ ID NOs: 18-25. A process comprising: a) passing a cell suspension comprising an entry T cell through a cell strain constriction, wherein a diameter of the constriction is a function of a diameter of the entry T cell in the suspension, thereby causing input T cell disturbances large enough for antigen and adjuvant to pass through to form a disturbed input T cell; and b) incubating the disturbed entry T cell with the antigen and adjuvant for a time sufficient to allow the antigen and adjuvant to enter the disturbed entry T cell; thus generating the modified T cell. It also relates to methods of using said T cells to modulate an immune response.

PE2020001395A 2018-03-12 2019-03-11 INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSES PE20211449A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862641987P 2018-03-12 2018-03-12
US201862738941P 2018-09-28 2018-09-28
US201962738941P 2019-01-18 2019-01-18
PCT/US2019/021705 WO2019178006A2 (en) 2018-03-12 2019-03-11 Intracellular delivery of biomolecules to modify immune response

Publications (1)

Publication Number Publication Date
PE20211449A1 true PE20211449A1 (en) 2021-08-05

Family

ID=77914169

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001395A PE20211449A1 (en) 2018-03-12 2019-03-11 INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSES

Country Status (1)

Country Link
PE (1) PE20211449A1 (en)

Similar Documents

Publication Publication Date Title
CO2018006699A2 (en) Scalable methods to produce a recombinant adeno-associated viral vector (aav) in a serum-free suspension cell culture system suitable for clinical use
EA201992469A1 (en) ANTIGEN SPECIFIC IMMUNE EFFECTIVE CELLS
AR103162A1 (en) ANTI-C5 ANTIBODIES AND METHODS FOR USE
PE20191324A1 (en) OPTIMIZATION OF ANTIBODIES THAT BIND TO THE LYMPHOCYTE ACTIVATION GENE 3 (LAG-3) AND USES OF THEM
MX2019011504A (en) Tumor antigen presentation inducer constructs and uses thereof.
MX2019010575A (en) Method for producing multispecific antibodies.
FR3068366B1 (en) METHOD FOR PRODUCING ERYTHROID PROGENITORS
BR112016028512A8 (en) method of culturing a mammalian cell and method of producing a recombinant protein
BR112016012229A2 (en) polypeptide production methods
PE20190415A1 (en) HUMANIZED ANTI-BASIGIN ANTIBODIES AND THE USE OF THEM
CO2022007238A2 (en) Chimeric antigen receptor t-cell therapy
PE20211449A1 (en) INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSES
ES2096650T3 (en) IMPROVEMENT OF THE ASSOCIATION OF EXOGENOUS PEPTIDES WITH MHC CLASS I MOLECULES IN CELLS OF THE IMMUNE SYSTEM.
ES2652267T3 (en) Method for efficient isolation of microbial DNA from blood
MX2021001890A (en) Production methods for viral vectors.
AR088428A1 (en) MULTIPLEXED TEST BASED ON SELF-ASSEMBLED SPHERES FOR ANTIGEN SPECIFIC ANTIBODIES
AR110908A1 (en) PROMOTER CONSTRUCTION FOR SYNTHESIS OF PROTEINS FREE OF CELLS
PL439808A1 (en) Methods and compositions of cell cultures for the production of antibodies
MX2022008298A (en) Antibody for skewing sex ratio and methods of use thereof.
AR115304A1 (en) STEM / PROGENITOR CELLS OF THE DUODENAL BRUNNER GLANDS AND METHODS FOR THEIR ISOLATION AND USE
EP3740226A4 (en) Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same
JP2015536145A5 (en)
MX2023005570A (en) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes.
PE20171734A1 (en) SPECIFIC MONOCLONAL ANTIBODIES OF HUMAN METAPNEUMOVIRUS VIRUS (HMPV) ANTIGEN M AND THEIR USE IN A DIAGNOSTIC METHOD
Carnell et al. Production of lentiviral vectors pseudotyped with influenza neuraminidase (NA)